| Dunes Family Pharmacy Inc | |
| 101 Tower Rd, Ste 130, Dakota Dunes, South Dakota 57049 | |
| (605) 242-5050 |
| Name | Dunes Family Pharmacy Inc |
|---|---|
| Organization Name | Dunes Family Pharmacy Inc |
| Location | 101 Tower Rd, Ste 130, Dakota Dunes, South Dakota 57049 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (605) 242-5050 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Among Chinese women who are survivors of intimate partner violence, an advocacy intervention that included empowerment sessions and telephone support from social workers did not result in a clinically meaningful improvement in depressive symptoms, according to a study in the August 4 issue of JAMA, a theme issue on violence and human rights.
The findings of a comprehensive review of the placebo phenomenon and its consequences for clinical medicine are contained in a new article, "Placebo and the New Physiology of the Doctor-Patient Relationship," (http://bit.ly/14QfSur) published in Physiological Reviews.
› Verified 3 days ago
| NPI Number | 1184216889 |
| Organization Name | DUNES ANESTHESIA PC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 101 Tower Rd Ste 103, Dakota Dunes, SD 57049 |
| Phone Number | 605-217-7246 |
News Archive
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Among Chinese women who are survivors of intimate partner violence, an advocacy intervention that included empowerment sessions and telephone support from social workers did not result in a clinically meaningful improvement in depressive symptoms, according to a study in the August 4 issue of JAMA, a theme issue on violence and human rights.
The findings of a comprehensive review of the placebo phenomenon and its consequences for clinical medicine are contained in a new article, "Placebo and the New Physiology of the Doctor-Patient Relationship," (http://bit.ly/14QfSur) published in Physiological Reviews.
› Verified 3 days ago
| NPI Number | 1205010204 |
| Organization Name | DUNES FAMILY PHARMACY INC |
| Type | Community/Retail Pharmacy |
| Address | 101 Tower Road, Ste 130, Dakota Dunes, SD 57049 |
| Phone Number | 605-242-5050 |
News Archive
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Among Chinese women who are survivors of intimate partner violence, an advocacy intervention that included empowerment sessions and telephone support from social workers did not result in a clinically meaningful improvement in depressive symptoms, according to a study in the August 4 issue of JAMA, a theme issue on violence and human rights.
The findings of a comprehensive review of the placebo phenomenon and its consequences for clinical medicine are contained in a new article, "Placebo and the New Physiology of the Doctor-Patient Relationship," (http://bit.ly/14QfSur) published in Physiological Reviews.
› Verified 3 days ago
News Archive
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Among Chinese women who are survivors of intimate partner violence, an advocacy intervention that included empowerment sessions and telephone support from social workers did not result in a clinically meaningful improvement in depressive symptoms, according to a study in the August 4 issue of JAMA, a theme issue on violence and human rights.
The findings of a comprehensive review of the placebo phenomenon and its consequences for clinical medicine are contained in a new article, "Placebo and the New Physiology of the Doctor-Patient Relationship," (http://bit.ly/14QfSur) published in Physiological Reviews.
› Verified 3 days ago
Dunes Family Pharmacy Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 101 Tower Rd, Dakota Dunes, South Dakota 57049 Phone: (605) 242-5050 | |
Redlers Long Term Care Llc Type: Long Term Care Pharmacy Location: 317 Dakota Dunes Blvd, Dakota Dunes, South Dakota 57049 Phone: (605) 235-1552 | |
Hanger Clinic Type: Durable Medical Equipment & Medical Supplies Supplier Location: 330 Dakota Dunes Blvd Ste 150, Dakota Dunes, South Dakota 57049 Phone: (605) 232-0066 | |
Dunes Eye Consultants Type: Medicare Supplier Location: 305 Dakota Dunes Blvd, Dakota Dunes, South Dakota 57049 Phone: (605) 232-6900 | |
Bruening Eye Specialists Type: Medicare Supplier Location: 101 Tower Rd, Dakota Dunes, South Dakota 57049 Phone: (605) 217-4500 |